Organon Revenue Drops 4% in Q1 2026 Amid Women’s Health Decline
Event summary
- Organon reported Q1 2026 revenue of $1.46 billion, down 4% year-over-year and 9% excluding foreign exchange effects.
- Women’s Health revenue declined 16% as-reported due to decreased demand for Nexplanon® and oral contraceptives in key markets.
- Biosimilars revenue increased 23% driven by strong performance of Hadlima® and contributions from new assets Bildyos® and Bilprevda®.
- Net income rose to $146 million, or $0.55 per diluted share, up 68% year-over-year despite a 7% decline in gross margin.
The big picture
Organon’s Q1 2026 results reflect broader industry pressures in women’s health, particularly in contraceptives and fertility treatments. The company’s biosimilars segment shows resilience, but the pending acquisition by Sun Pharma introduces uncertainty about future strategic direction. With $8.57 billion in debt and a focus on cost management, Organon must balance short-term financial performance with long-term growth initiatives.
What we're watching
- Product Strategy
- How Organon will address the decline in Women’s Health revenue amid market contraction and pricing pressure.
- M&A Dynamics
- Whether the pending acquisition by Sun Pharma will accelerate or complicate Organon's strategic realignment.
- Operational Efficiency
- The pace at which Organon can improve gross margins amid unfavorable pricing and product mix challenges.
Related topics